2026NEW
Orforglipron
Mechanism: Oral small-molecule GLP-1 receptor agonist
Indication: Obesity and type 2 diabetes (under regulatory review)
New Drugs
Recently approved drugs
Newer molecules and landmark approvals — frequently asked in current-affairs sections of pharmacy exams.
2025NEW
Suzetrigine
Mechanism: Selective NaV1.8 sodium channel blocker (non-opioid)
Indication: Moderate to severe acute pain
2025NEW
Gepotidacin
Mechanism: Triazaacenaphthylene bacterial topoisomerase inhibitor
Indication: Uncomplicated urinary tract infection
2025NEW
Lenacapavir (twice-yearly)
Mechanism: HIV-1 capsid inhibitor
Indication: HIV pre-exposure prophylaxis
2025NEW
Atrasentan
Mechanism: Selective endothelin A receptor antagonist
Indication: IgA nephropathy proteinuria
2024NEW
Resmetirom
Mechanism: Thyroid hormone receptor-β agonist
Indication: NASH/MASH with liver fibrosis
2024NEW
Xanomeline + Trospium
Mechanism: Muscarinic M1/M4 agonist with peripheral antagonist
Indication: Schizophrenia
2024NEW
Donanemab
Mechanism: Anti-amyloid (N3pG) monoclonal antibody
Indication: Early symptomatic Alzheimer's disease
2024NEW
Aprocitentan
Mechanism: Dual endothelin receptor antagonist
Indication: Resistant hypertension
2024NEW
Sotatercept
Mechanism: Activin signalling inhibitor
Indication: Pulmonary arterial hypertension
2024NEW
Ensifentrine
Mechanism: Inhaled dual PDE3/PDE4 inhibitor
Indication: COPD maintenance
2023NEW
Lecanemab
Mechanism: Monoclonal antibody against amyloid-β protofibrils
Indication: Early Alzheimer's disease
2023NEW
Zuranolone
Mechanism: Neuroactive steroid, GABA-A positive allosteric modulator
Indication: Postpartum depression
2023NEW
Fezolinetant
Mechanism: Neurokinin-3 receptor antagonist
Indication: Menopausal hot flushes
2023NEW
Nirmatrelvir + Ritonavir
Mechanism: SARS-CoV-2 main protease inhibitor (ritonavir boosted)
Indication: COVID-19 in high-risk adults
2023NEW
Sotagliflozin
Mechanism: Dual SGLT1/SGLT2 inhibitor
Indication: Heart failure risk reduction
2023NEW
Tirzepatide (Zepbound)
Mechanism: Dual GIP and GLP-1 receptor agonist
Indication: Chronic weight management
2014
Dapagliflozin
Mechanism: SGLT2 inhibitor
Indication: Type 2 diabetes, later HF and CKD
2012
Bedaquiline
Mechanism: Mycobacterial ATP synthase inhibitor
Indication: Multidrug-resistant tuberculosis